FDA approval of a generic nintedanib formulation; regulatory action without clinical trial data or comparative efficacy claims in this record.
Reported
Approval statusApproved
Approval date2026-04-02
Formulation strengths100 mg and 150 mg
Loading
Company
1 development in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
FDA approval of a generic nintedanib formulation; regulatory action without clinical trial data or comparative efficacy claims in this record.